- Home
- PEGA vs GRFS Comparison
PEGA vs GRFS Comparison
Compare PEGA & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | GRFS |
|---|---|---|
| Founded | 1983 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.5B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | PEGA | GRFS |
|---|---|---|
| Price | $34.21 | $7.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 2 |
| Target Price | ★ $60.13 | $10.15 |
| AVG Volume (30 Days) | ★ 2.4M | 587.0K |
| Earning Date | 04-21-2026 | 07-28-2022 |
| Dividend Yield | 0.34% | ★ 1.80% |
| EPS Growth | ★ 91.89 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $682,695,000.00 | N/A |
| Revenue This Year | $15.99 | $4.49 |
| Revenue Next Year | $11.90 | $6.42 |
| P/E Ratio | $187.47 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.23 | $7.39 |
| 52 Week High | $105.50 | $11.14 |
Technical Indicators
Market Signals| Indicator | PEGA | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 45.35 |
| Support Level | N/A | $7.52 |
| Resistance Level | $44.95 | $9.78 |
| Average True Range (ATR) | 1.52 | 0.22 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 34.45 | 37.82 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.